Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos
about
Next-generation prognostic assessment for diffuse large B-cell lymphomaDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentTrends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma.Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study.Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era.Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaEfficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraManagement Strategies for Elderly Patients with Diffuse Large B-Cell LymphomaPrognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP.Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients.Treatment of the elderly patient with diffuse large B cell lymphoma.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraA clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma.Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma.Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.Comparison of Prognostic Indices in Japanese Patients with Diffuse Large B-cell Lymphoma in the Yonago Area.
P2860
Q26796428-B2A28470-B508-458D-A4A0-72DCA227F6E0Q30235296-0ED09C3A-5056-4B3B-96D9-070514E4AB72Q30967984-6855AD93-CA19-4DD6-AB5C-E85FEBC4DA56Q33440896-FD3988EB-C108-4652-9731-B112844DFBB3Q33945770-080B0540-3F91-4F13-BC27-FC23F23124EDQ35236068-6FF934AD-B8FA-467B-B232-8FB4DDDD27ACQ35989968-E48CEF49-146A-45C6-A9AC-D443F82B5A3EQ36255792-D6990CE6-36CD-47FE-9975-9ED64276CAF5Q36416332-5466F790-350E-499B-BABD-4BB59243E500Q36482438-694CBF06-FD0A-426D-92E0-E2F2AF0D2190Q36710788-A158DEFD-4B91-43B7-AA77-D4E18E99E09AQ36908665-C4D4003C-9063-4ED9-AE60-B0D26EE0FDA7Q36939926-7E5FFA10-08CF-4434-AB03-749F93685BFCQ36949798-069EE697-21B6-4258-A492-EA592A1C1302Q37300619-C47AAE9A-01D1-4152-AF00-5BD1AD977787Q37685724-71332F68-BF56-4C34-B85F-83D7E01E5A6AQ37706051-FFC32972-D247-485F-BD88-2C98EE589A17Q37998553-ADB2086B-9F50-4789-B2EC-A6C2A004852AQ38061883-5C8C4140-8AE7-42AB-9F3E-9D826D1298BBQ38552083-777D8CC3-ADD5-49A3-AC47-7B33F3E9711CQ40410427-83E805E4-09D7-4A5E-A605-1EA1066DD1CEQ40603238-B1D6B4B2-DFCC-4F47-96A7-512049B6E310Q41127479-10674485-8339-4180-BFB9-0BCAF97EE59EQ41513921-F3524BF3-1660-4DFD-AECA-066D0EE3107BQ41618393-5361CEFF-A59A-45BF-BB37-11385C5AC890Q43529478-B9C339C8-1593-4AAB-92E6-DC54DC046385Q43834616-CFC034FE-7950-4AC4-9BFA-05FDBD804536Q44380574-8C573759-E11A-412E-9779-0B3082138599Q44950915-9024B870-B335-4F3F-9D64-8FB5782A9233Q48266876-48BC335D-9631-40EF-83F1-A8C994C5057BQ48281350-5D6E6D9D-CE77-4D5E-98EE-8C8CC0042860Q48319171-09E738B2-7851-49E6-81B3-8ECFFC3A726DQ52723050-F55102D5-1625-4319-82F1-714C16EE5385
P2860
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comparison of conventional pro ...... 70 years in an elderly prognos
@ast
Comparison of conventional pro ...... 70 years in an elderly prognos
@en
type
label
Comparison of conventional pro ...... 70 years in an elderly prognos
@ast
Comparison of conventional pro ...... 70 years in an elderly prognos
@en
prefLabel
Comparison of conventional pro ...... 70 years in an elderly prognos
@ast
Comparison of conventional pro ...... 70 years in an elderly prognos
@en
P2093
P2860
P50
P1476
Comparison of conventional pro ...... 70 years in an elderly prognos
@en
P2093
Bruce A Peterson
Edie A Weller
Haiyan Chen
Randy D Gascoyne
Ranjana H Advani
Richard I Fisher
Sandra J Horning
Thomas M Habermann
Vicki A Morrison
P2860
P304
P356
10.1111/J.1365-2141.2010.08331.X
P407
P577
2010-10-01T00:00:00Z